216761

WiSe 18/19: The Drug Discovery Process in the Pharmaceutical Industry - From hit to clinical candidate / Wirkstoffentwicklung - Vom hit zum klinischen Kandidaten

Roman Hillig, Christoph Rademacher

Additional information / Pre-requisites

This course can be attended independently to the course "The Drug Discovery Process in the Pharmaceutical Industry - From target to hit identification / Wirkstoffentwicklung - Vom target zur hit-Findung" (LV-Nr. 216762), which takes place in the summer semeste. close

Comments

Drug discovery is a highly interdisciplinary process which involves project teams of pharmacologists, medicinal chemists, protein chemists/molecular biologists, structural biologists and computational chemists. The lecture series will provide an introduction to the drug discovery process as run in the pharmaceutical industry, from target identification and validation, via hit finding methods and the hit-to-lead process, to lead optimization, development and clinical studies. Emphasis will be on the contributions protein crystallography and further biophysical methods (such as NMR, ITC and SPR) can make during target selection, hit prioritization and lead optimization. In the second half of the course, typical target families such as protein kinases, nuclear hormone receptors and proteases will be discussed in the context of available crystal structures, and co-complex crystal structures with lead and drug molecules will be analysed in detail: How do drug molecules interact with their target proteins, and what can we learn from their optimisation process? The aim of the course is to develop an understanding of the molecular mechanisms of drug discovery. Overview (topics of the lectures): Protein-Ligand Interactions Hit-to-Lead and Lead Optimization; ADMEtox; Chemoinformatics; Molecular Modeling; Drug classes: Biologics and Carbohydrates; Typical target families (GPCRs, epigenetic targets) Kontakt: Dr. R. Hillig: roman.hillig@bayer.com Dr. C. Rademacher: christoph.rademacher@mpikg.mpg.de close